# A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer

> **NCT06757335** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Hinova Pharmaceuticals Inc.** · enrollment: 204 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** HP568
- **DRUG:** HP568 in combination with palbociclib

## Key facts

- **NCT ID:** NCT06757335
- **Lead sponsor:** Hinova Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-07
- **Primary completion:** 2026-01-31
- **Final completion:** 2026-11-27
- **Target enrollment:** 204 (ESTIMATED)
- **Last updated:** 2025-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06757335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06757335, "A Phase I/II Trial to Evaluate Oral HP568 Tablets in Patients with ER+/HER2 Advanced Breast Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06757335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*